Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Effects of Additive Therapy With Spironolactone on Proteinuria in Diabetic Patients Already on ACE Inhibitor or ARB Therapy

(2016) Mohammad G. Saklayen et al.   JOURNAL OF INVESTIGATIVE MEDICINE

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

(2015) George L. Bakris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis

(2015) M. Jun et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Cardiovascular actions of mineralocorticoid receptor antagonists in patients with chronic kidney disease: A systematic review and meta-analysis of randomized trials

(2015) Khai P Ng et al.   JOURNAL OF THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM

Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors

(2015) Matthew R. Weir et al.   NEW ENGLAND JOURNAL OF MEDICINE

Diabetic Kidney Disease: A Report From an ADA Consensus Conference

(2014) Katherine R. Tuttle et al.   DIABETES CARE

Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis

(2014) H. J. Lambers Heerspink et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial

(2014) Nathan R Hill et al.   Trials

Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial

(2014) Katsuyuki Ando et al.   Lancet Diabetes & Endocrinology

Combined Angiotensin Inhibition for the Treatment of Diabetic Nephropathy

(2013) Linda F. Fried et al.   NEW ENGLAND JOURNAL OF MEDICINE

Eplerenone Attenuates Pulse Wave Reflection in Chronic Kidney Disease Stage 3–4 - A Randomized Controlled Study

(2013) Lene Boesby et al.   PLoS One

Urinary corticosteroid excretion predicts left ventricular mass and proteinuria in chronic kidney disease

(2012) Emily P. McQuarrie et al.   CLINICAL SCIENCE

Spironolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study

(2012) S. E. Nielsen et al.   DIABETIC MEDICINE

The Enhanced Renin-Angiotensin-Aldosteron System Pharmacological Blockade - Which is the Best?

(2012) Leszek Tylicki et al.   KIDNEY & BLOOD PRESSURE RESEARCH

Chapter 3: Management of progression and complications of CKD

(2012)   Kidney International Supplements

Microalbuminuria breakthrough under chronic renin–angiotensin–aldosterone system suppression

(2011) Cesar Cerezo et al.   JOURNAL OF HYPERTENSION

Moderate Antiproteinuric Effect of Add-On Aldosterone Blockade with Eplerenone in Non-Diabetic Chronic Kidney Disease. A Randomized Cross-Over Study

(2011) Lene Boesby et al.   PLoS One

A Randomized, Double-Blind, Placebo-Controlled Trial of Spironolactone on Carotid Intima-Media Thickness in Nondiabetic Hemodialysis Patients

(2010) A. Vukusich et al.   Clinical Journal of the American Society of Nephrology

Increased serum potassium affects renal outcomes: a post hoc analysis of the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial

(2010) Y. Miao et al.   DIABETOLOGIA

Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis

(2010)   LANCET

Aldosterone Antagonists for Preventing the Progression of Chronic Kidney Disease: A Systematic Review and Meta-analysis

(2009) S. D. Navaneethan et al.   Clinical Journal of the American Society of Nephrology

Hyperkalemia Risk in Chronic Kidney Disease

(2009) Domenic A. Sica   HYPERTENSION

Mechanisms of Impaired Potassium Handling With Dual Renin-Angiotensin-Aldosterone Blockade in Chronic Kidney Disease

(2009) Richard A. Preston et al.   HYPERTENSION

Hyperkalemia as a Constraint to Therapy With Combination Renin-Angiotensin System Blockade: The Elephant in the Room

(2009) Murray Epstein   Journal of Clinical Hypertension

Effect of Spironolactone on Left Ventricular Mass and Aortic Stiffness in Early-Stage Chronic Kidney Disease

(2009) Nicola C. Edwards et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy

(2009) U. F. Mehdi et al.   JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY

Antifibrotic Effects of Aldosterone Receptor Blocker (Spironolactone) in Patients with Chronic Kidney Disease

(2009) Ibrahim Guney et al.   RENAL FAILURE

Triple Pharmacological Blockade of the Renin-Angiotensin-Aldosterone System in Nondiabetic CKD: An Open-Label Crossover Randomized Controlled Trial

(2008) Leszek Tylicki et al.   AMERICAN JOURNAL OF KIDNEY DISEASES

Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events

(2008)   NEW ENGLAND JOURNAL OF MEDICINE